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ABSTRACT
Objectives: Since 2006, general practitioners (GPs) in
England, UK, have been incentivised to keep a register
and monitor patients with chronic kidney disease
(CKD) stages 3–5. Despite tensions and debate around
the merit of this activity, there has been little qualitative
research exploring clinician perspectives on monitoring
early-stage CKD in primary care. This study aimed to
examine and understand a range of different healthcare
professional views and experiences of identification
and monitoring in primary care of early-stage CKD, in
particular stage 3.
Design: Qualitative design using semistructured
interviews.
Setting: National Health Service (NHS) settings across
primary and secondary care in South West England,
UK.
Participants: 25 clinicians: 16 GPs, 3 practice nurses,
4 renal consultants and 2 public health physicians.
Results: We identified two related overarching themes
of dissonance and consonance in clinician perspectives
on early-stage CKD monitoring in primary care.
Clinician dissonance around clinical guidelines for CKD
monitoring emanated from different interpretations of
CKD and different philosophies of healthcare and moral
decision-making. Clinician consonance centred on the
need for greater understanding of renal decline and
increasing proteinuria testing to reduce overdiagnosis
and identify those patients who were at risk of
progression and further morbidity and who would
benefit from early intervention. Clinicians
recommended adopting a holistic approach for patients
with CKD representing a barometer of overall health.
Conclusions: The introduction of new National
Institute for Health and Care Excellence (NICE) CKD
guidelines in 2014, which focus the meaning and
purpose of CKD monitoring by increased proteinuria
testing and assessment of risk, may help to resolve
some of the ethical and moral tensions clinicians
expressed regarding the overmedicalisation of patients
with a CKD diagnosis.
INTRODUCTION
Since the international adoption of the
Kidney Disease Outcomes Quality Initiative
(KDOQI) in 2002 (modiﬁed in 2012),1
increasing numbers of people have received
a diagnosis of chronic kidney disease (CKD).
The stimulus for the 2002 framework was the
absence of an agreed deﬁnition and classiﬁ-
cation of kidney disease and evidence that
people were experiencing avoidable harm
through late presentation.2 In 2010, the
prevalence of CKD was described as having
reached ‘epidemic proportions’3 having
increased from 0.3% in 2005 to 3.9% in
2009.4 Between 2009 and 2010, CKD was
thought to have accounted for 1.3% of the
total UK healthcare budget with the majority
of patients being managed within primary
care.5
UK national guidance for the early identiﬁ-
cation and management of adults with CKD
published in 2008 by the National Institute
Strengths and limitations of this study
▪ This qualitative study explores how clinicians
responsible for patients with chronic kidney
disease (CKD) view guidance on identification
and monitoring of early-stage CKD.
▪ Our purposive sampling strategy recruited
several strata of professional groups caring for a
range of patients.
▪ The qualitative data provide a deeper understand-
ing of how clinicians manage complex ethical
and philosophical tensions in their efforts to
provide good patient care.
▪ The qualitative findings from our purposive
sample are not intended to be representative but
highlight important insights.
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for Health and Care Excellence (NICE) recommends
regular follow-up testing of all patients with CKD from
stages 3–5. CKD stages are based on estimated glomeru-
lar ﬁltration rate (eGFR) representing the level of
kidney function.6 Since 2006, general practitioners
(GPs) in England have been incentivised to keep a regis-
ter of patients with CKD stages 3–5 through the Quality
and Outcomes Framework (QOF). The rationale for
CKD monitoring was for early identiﬁcation of decline
in renal function and management of cardiovascular
risk.2 However, since the introduction of the CKD QOF
register, there have been tensions around the manage-
ment of people with CKD. In diagnosing CKD, the use
of single eGFR measurements and ‘inappropriate use’ of
microalbuminuria7 are thought to have contributed to
missed diagnoses and overclassiﬁcations of CKD. It is
argued that these problems have created increased GP
workloads/use of health resources and ‘suboptimal man-
agement’ of patients in primary care.4 8
Concerns and tensions around CKD as a new disease
paradigm7 have been the subject of debate in some key
biomedical journals over the last decade, particularly
over stable early-stage CKD. Minor reductions in eGFR
alone without indicators of glomerular damage may be
considered an aspect of normal ageing and these issues
have been articulated in the ‘too much medicine’, ‘bad
medicine’9 and the ‘medicalisation of normal ageing’
debates.10 Ethical issues around labelling people with a
disease, who may never progress, were thought to
present a potential for harm to patients10 as were con-
cerns around the accuracy of diagnostic tests for CKD
and the overdiagnosis of people over 75 years being
labelled with the disease.11 12 The clinical signiﬁcance of
low eGFR in the elderly has raised considerable debate.2
Reﬂecting these concerns, some clinicians did not
accept the CKD disease paradigm,13 preferring not to
disclose early-stage CKD, particularly in older patients.14
There were also concerns about the possible harm to
elderly patients in pursuing target-driven blood pressure
reduction in CKD.12 The evidence for these targets was
criticised for being drawn from trials that ‘often exclude
the elderly and those with mild-to-moderate CKD’.12
To date, qualitative studies examining the manage-
ment of CKD in primary care have highlighted a
number of tensions that presented barriers to optimal
management.13 15 16 There was uncertainty around the
merits of disclosure of a CKD diagnosis, particularly in
older people.15 16 Primary care clinicians were also
reluctant to use the label ‘CKD’ with their patients, pre-
ferring to use terminology deemed less anxiety provok-
ing and centred around reassurance.13 15 16 However,
while these strategies protected patients from the emo-
tional impact of a CKD diagnosis, it also limited oppor-
tunities for discussion with patients about kidney health
and self-care that could help protect them from further
kidney damage. This study aimed to examine the views
and experiences of range of clinicians and to explore in
more depth the issues of tension previously identiﬁed,
in particular how clinicians understand and deﬁne early-
stage CKD in relation to current guidelines and how this
impacts on their approach to disclosure and care.
METHODS
Semistructured interviews were conducted with primary
care clinicians, renal consultants and public health phy-
sicians across South West England, UK.
Participant sampling and recruitment
Purposive sampling was used to capture maximum vari-
ation in experience of clinicians with responsibility for
patients with CKD, either individually or at population
level. Thirteen general practices in Bristol were purpos-
ively sampled to include practices serving a range of
deprived and afﬂuent areas using the practice-level
indices of multiple deprivation (IMD) scores,17 size of
patient list, percentage of older people and number of
patients on the CKD register. To investigate experiences
of CKD identiﬁcation and monitoring in primary care,
GPs and practice nurses were purposively sampled for
maximum variation across year of qualiﬁcation and GP
practice. In addition, to contextualise the ﬁndings, we
opportunistically interviewed four renal consultants and
two public health physicians regarding their views on
CKD3 monitoring.
Data collection
The majority of interviews were conducted at the clini-
cian’s place of work and four interviews were conducted
over the telephone. All interviews were conducted by a
non-clinical researcher (RS) and lasted between 30 and
60 min. Although a topic guide was used to focus the
interviews, participants were able to speak freely about
their experiences and raise topics not covered by the
guide. The topic guide was informed by a review of rele-
vant literature and suggestions from our multiprofes-
sional study team and advisory group and modiﬁed as
data analysis progressed. Topics included perceptions of
early-stage CKD (stage 3), experiences of CKD diagnosis,
management and monitoring and opinions of current
guidelines.
With written informed consent, all interviews were
audio-recorded and transcribed verbatim, anonymised
and imported into NVivo V.10 qualitative software
program to aid management and analysis of data.
Data analysis
RS led the analysis using an inductive thematic
approach18 involving a process of constant comparison
between cases.19 Analysis began alongside data collec-
tion, with ideas from early analysis informing later data
collection in an iterative process until data indicated sat-
uration.20 Analysis of individual transcripts started with
open coding grounded in the data. This generated an
initial coding framework, which was added to and
reﬁned as new data were gathered. Codes were gradually
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built into broader categories through comparison across
transcripts, and higher level recurring themes were
developed. To enhance analysis and enable team discus-
sion and interpretation, team members (RS and JH)
independently coded transcripts; any discrepancies were
discussed to achieve a coding consensus and maximise
rigour. The data, disconﬁrming views, coding frame-
works and development of higher order and ﬁnal
themes were discussed by the multidisciplinary research
team KB, JE, GF and JH to ensure credibility and
conﬁrmability.21
RESULTS
A total of 25 clinicians were recruited and interviewed:
16 GPs, 3 practice nurses, 4 renal consultants and 2
public health physicians (table 1). Interviews were con-
ducted between February and September 2014. Analysis
led to the development of the key emergent themes out-
lined below. All initials of participants refer to
pseudonyms.
Understanding the tensions: clinician dissonance around
early-stage CKD monitoring
Cognitive dissonance22 refers to the discomfort experi-
enced when an individual holds contradictory beliefs, ideas
or values or is confronted by new information that conﬂicts
with existing beliefs, ideas or values. Most GPs expressed
initial discomfort about being incentivised through QOF to
keep a register and monitor of patients with CKD stage 3, as
it contradicted existing beliefs around the meaning and
status of mild reduction in kidney function:
I think when it ﬁrst came in as an idea…we all rolled our
eyes and went ‘Oh my God’, you know? They’re creating
an illness that doesn’t exist. (GPD)
The introduction of ‘CKD’ as a new disease construct
conﬂicted with most GP professional values and per-
sonal understandings of general practice medicine. GPs
referred to general practice medicine as primarily
responding to patients’ symptoms and explained how
monitoring activities and screening programmes were
changing the way they practised. GPs experienced dis-
sonance between what they felt was their role as general-
ists in caring for individual patients and what was being
recommended by English national guidelines23 and
incentivised via QOF, at a population level.
People get confused between screening and actually
picking disease up, because people present with symp-
toms, which is actually what most medicine is…this idea
of bringing in back-door screening…you know, I think
they should be honest about what they’re actually trying
to do and particularly when you’re looking at harm to
patients—increased anxiety, labelling…interesting areas
for the next ﬁve years of discussion, but I suspect it will
go down more and more—disease labelling, monitor-
ing…that’s where we’ll go. (GPJ)
GPs also felt tension between their experiences of
managing patients with impaired kidney function in
general practice and the rationale for labelling patients
with a disease. GPs felt that the introduction of CKD
monitoring in primary care was driven by specialists
informed by experience of advanced, progressive kidney
disease which they perceived as rare in primary care. As
a result, GPs felt that patients were being medicalised
and potentially harmed by being given a chronic disease
label that did not relate to signiﬁcant renal pathology.
I don’t think that the people who introduced this were
actually aware of the natural history of 95% of eGFRs of
60…it was actually looked at from the wrong end of the
telescope ie, you know, it was the specialist looking at the
people that ended up with them with kidney failure who
then assumed that…this was the usual situation as
opposed to being aware, actually, that it doesn’t end up
as kidney failure out in the community…I expect GPs are
probably more aware of monitoring eGFR levels, which is
what we’re really talking about here, rather than trying to
label it as a disease. (GPC)
We medicalise everything…instead of normalising, we’re
making people ill…and we’re putting labels on them
which don’t really beneﬁt them at all most of the time….
and the patient rarely, rarely beneﬁts…“It’s not really an
illness—it’s a bit like being 5 foot 2”… for the vast major-
ity of the patients that we see, it has no practical import-
ance or relevance at all. (GPA)
A renal consultant also experienced dissonance
around classifying ‘disease’ in patients where the eGFR
levels could be considered ‘normal’ in relation to age:
The question of whether a reduced creatinine clearance,
or estimated GFR…is normal or abnormal, i.e. disease
state or normal for age. There’s a philosophical debate
that’s complicated and unnecessarily polarised in my
opinion. (Renal Consultant A)
The clinician dissonance rooted in tensions between
perceptions of individual and population approaches to
health, conceptions of ‘normal’ and generalism and spe-
cialism and also between conﬂicting philosophical and
ethical approaches to biomedicine. GPs experienced
feelings of dissonance around two contrasting biomed-
ical ethical frameworks—consequentialism and deontol-
ogy. These approaches embody different conceptions of
moral obligation that can inﬂuence clinician decision-
making on whether to disclose a diagnosis of CKD.
Most clinicians adopted a (benign) paternalistic
approach to disclosure of early-stage CKD that appeared
to be underpinned by consequentialism where the
outcome or consequences of disclosure of CKD is con-
sidered the important factor. The logic of this approach
being: If very few people progress from a chronic condi-
tion to established renal failure, can it be called a
disease? If not, why disclose, label, monitor and poten-
tially alarm people with mildly reduced kidney function?
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People have published papers saying a great proportion
of people with CKD don’t know about it. That may actu-
ally be just ﬁne because the GPs may be playing a good
game and saying I’m not going to bother this patient
with having a GFR of 59 because I know that although it
qualiﬁes as CKD 3 it’s not gonna make any difference to
how I manage that patient and I think that’s good medi-
cine rather than, you know, dumping a disease label. I’m
sure that you can harm people by saying you’ve got
chronic kidney disease and it’s stage 3 out of 5 …and
walk away and I’m sure people have been harmed by
that. (Renal Consultant B)
In contrast, some, more recently qualiﬁed GPs,
appeared to adopt a deontological approach to disclos-
ure. In this moral framework, the rights of patients,
respect for patient autonomy and shared decision-
making practices are likely to be the driving factors in
decision-making on disclosure of CKD.
My personal policy I would always disclose…generally
speaking I would always explain the diagnosis. I always say
it’s er, it’s a horrible name for this condition and it’s not,
you know it’s misleading and I try and make less of a big
deal about it…(GPG)
Although some GPs preferred to disclose a diagnosis
of early-stage CKD, they still felt ambivalent about the
term CKD and how being labelled as having ‘chronic
kidney disease’ was potentially misleading for patients
with non-progressive, early-stage CKD.
Identifying agreement: clinician consonance
The meaning of renal decline
Clinicians generally agreed that there is a mismatch
between the term ‘chronic kidney disease’ and the
ontology of renal decline. Most clinicians conceptualised
the broader physiological meaning and clinical implica-
tions of reduced kidney function as primarily a barom-
eter of physiological challenge and quality of care.
I would argue that kidney function gives us a barometer
on the quality of clinical care and the extent of clinical
challenge or metabolic challenge or physiological chal-
lenge … So the kidney tells you about the path of
physiological challenge… If you measure the protection
of the kidney then it tells you about the quality of…
medical clinical care. (Renal Consultant C)
The majority of clinicians understood the ontology
and meaning of renal impairment as an ‘epiphenom-
enon’ of other diseases rather than a discrete disease
entity.
Is it more an epiphenomenon of their other diseases,
their hypertension and their diabetes rather than being
an unpleasant independent nasty causative pathology?…
So, yes, that is true, ok—you’re not gonna do anything
renal speciﬁc—but in fact for a lot of the common condi-
tions that cause CKD i.e. diabetes, hypertension, vascular
disease, you’re not practically gonna be doing anything
very specialised in renal clinics than you are gonna do in
GP clinics. (Renal Consultant A)
I think with CKD it’s always going to be secondary pre-
vention [of other diseases]…Nor would I know whether
the effort targeted at CKD would be more effective than
having the same effort targeted at hypertension and dia-
betes. (Public Health Physician B)
Clinicians mostly agreed the main purpose of measur-
ing kidney function was in the context of comorbidities
such as diabetes and cardiovascular disease. Thus, they
argued that the management of CKD should be part of
the management of those primary conditions.
Clinicians agreed that renal function should not be
assessed in isolation and should be considered in the
context of the whole patient. Given this understanding
of kidney health, clinicians explained how a holistic
approach to the assessment and management of kidney
function would be more appropriate than a renal spe-
ciﬁc one.
What we need to do is to have a holistic approach… It
will tell you about whether or not you’ve spoken to some-
body and you’ve treated them with dignity and all of that
but I would equally argue that you can’t actually assess
somebody and manage them really well if at the same
time you’re treating them like, you know, a piece of meat,
you know, you can’t actually do that assessment…to
Table 1 Participant characteristics
Years since qualification
GP practice levels
of deprivation*
Participants N=25 <5 years 5–9 years 10+ years Deprived Affluent
GPs 16 1 3 12 8 8
Nurses 3 0 0 3 3 0
Years in current role
<5 years 5–9 years 10+ years
Renal consultants 4 0 2 2 All levels of deprivation
Public health physician 2 1 0 1 All levels of deprivation
*GP practice levels of deprivation measured as Index of Multiple Deprivation (IMD) quintile from GP practice postcode.17
GP, general practitioner.
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separate out that. If you’re just looking at the kidney
function, or the blood pressure, or, you know, the tem-
perature or if you’re looking at just one parameter you
can fall into the trap of treating pneumonia as opposed
to treating the person…If you did that for the kidney
you’d fail cos there’s kind of so many elements you need
to do….All the key elements, you know, come together.
(Renal Consultant D)
This extract draws attention to how the concept of
CKD is seen by clinicians to belie the actual complexity
and irreducibility of kidney health to a simple disease
construct.
How to improve identification of renal pathology
Clinicians in our study agreed that identiﬁcation of CKD
via measurement of eGFR within the current classiﬁca-
tion system (1–5) was a ‘blunt’ instrument for detecting
CKD.
Well, we see any awful lot of elderly people with CKD’s
just below 60 [eGFR] who have been like that for about
seven, eight years…And they’ve not progressed and I just
wondered if you know, if there was perhaps better infor-
mation about who really need to follow through it
because I think some people seem to have CKD but
never seem to progress and obviously some people do
and how you identify those people. Who we should be
concentrating on and perhaps calling it everybody who’s
got a CKD of 58 in every year to be monitored…hope-
fully there’ll sooner be more information about who will
be better to monitor rather than seeing and monitoring
everybody. (Practice Nurse B)
Most clinicians agreed that the additional detection of
proteinuria at all CKD stages was important for identify-
ing people who were at risk of progression and further
morbidity.
Well proteinuria, irrelevant of—you know the stage—the
staging system is really deﬁned but you know it’s not
great, but proteinuria is a stronger marker of poor
outcome be that vascular events or progression to end
stage renal failure or Acute Kidney Injury…proteinuria’s
been known for you know from ancient times and could
be related to poor outcomes—you know we just know
that even teeny weeny bits of proteinuria are generally
bad for you predominantly from the vascular perspective
to an extent and kidney perspective, so it’s moving
from a dialysis-centric approach to a health paradigm
where the kidneys are about vascular health. (Renal
Consultant D)
There are patients who you are measuring and they’ve
got a level of CKD and they’re 95 and you can quite hon-
estly say that they are not going to progress because they
have no proteinuria, they are unlikely to progress within
their normal lifespan …CKD 1 or 2 in a young person
with proteinuria may we be very relevant because they’ve
got plenty of years to progress but that might not be so
relevant in someone that’s 70, 80…So I think it’s very
hard to make a gross generalisation on it and I think you
do have to believe in each individual. (GPP)
However, clinicians felt that the current 2008 NICE
guidance24 did not encourage proteinuria testing at
CKD stages 1 and 2:
Proteinuria is a different matter but we are really not
encouraged to do the proteinuria until they are in to
CKD 3…We can do it, sure if we were encouraged to do
it before then. (GPF)
Some clinicians hoped that a more effective and
cheaper method of detection could be developed that
would identify patients who would beneﬁt from early
intervention:
It would be fantastic to have some way of better predict-
ing which of these people are going to have problems.
(GPD)
Clinicians agreed that kidney function was an indica-
tor of vascular health. From this standpoint, clinicians
argued for improved identiﬁcation of CKD in patients
who would beneﬁt from early intervention, making
early-stage CKD more meaningful for patients and clini-
cians. Improved identiﬁcation of early-stage CKD would
also help to better target National Health Service (NHS)
resources in primary care.
DISCUSSION
In understanding the tensions around the management
of early-stage CKD in primary care and in the context of
English national guidelines and QOF, we identiﬁed an
overarching theme of cognitive dissonance rooted in the
logic of contrasting models of healthcare and ethical
decision-making. The inclusion of the words ‘chronic’
and ‘disease’ in the term CKD was also identiﬁed as a
source of tension for clinicians. This term appears to be
too simplistic to describe a medical construct that pri-
marily relates to increased risk of morbidity, particularly
cardiovascular morbidity.
However, despite the issues of contention and disson-
ance around early-stage CKD monitoring in primary
care, our study found signiﬁcant agreement between
generalist and specialist clinicians’ regarding categoris-
ing people as having CKD on the basis of reduced
eGFRs alone. Clinicians perceived the current classiﬁca-
tion guidelines as oversimplifying a complex picture of
interdependent health and demographic factors, posing
ethical dilemmas around diagnosis and disclosure. Given
the multilayered nature of the CKD construct and over-
inclusive methods of identiﬁcation, based on national
guidance at the time,23 it is not surprising that the
purpose of monitoring early-stage CKD in primary care
seemed unclear and there was tension around disclosing
a potentially frightening diagnosis to patients.15 25
Clinicians agreed the need for improved detection of
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progressive renal disease and a move towards a patient-
centred, holistic assessment with renal function being
viewed as a marker of ‘well-being’ and vascular health.
Strengths and weaknesses of the study
This in-depth qualitative study on clinicians’ experiences
of managing early-stage CKD included a range of health
professionals. Purposive sampling for maximum vari-
ation across service sectors allowed us to examine a
broad range of clinician experiences and perspectives
on early-stage CKD monitoring in primary care. The
achievement of data saturation together with the rigour
of analysis increases the credibility of ﬁndings. The
majority of interviews were conducted before the publi-
cation in July 2014 of updated NICE clinical guidelines
for CKD and the results should be viewed in that light.26
Comparison with other studies
Our ﬁndings of tensions around early-stage CKD moni-
toring in primary care built upon ﬁndings from existing
qualitative studies on understanding the management of
CKD.13 15 16 Our study has deepened the understanding
by articulating how different ethical approaches to bio-
medicine and a preventative medicine agenda created
clinician tensions around the efﬁcacy of clinical guide-
lines for early-stage CKD monitoring. Our ﬁndings are
consistent with existing literature: GPs found diagnosing
CKD via eGFR tests a ‘hit-and-miss’ affair and reported
feeling anxious about telling patients with early-stage
CKD of their diagnosis.13 15 23 Recent research informed
by the principles of ‘minimally disruptive medicine’27
has addressed the concerns expressed by our partici-
pants and demonstrated that it is possible to provide
information about CKD without having a detrimental
effect on patient anxiety.28
Reﬂecting the ethical dilemmas reported by clinicians
in our ﬁndings, a kidney-related study in clinical ethics29
found that although doctors have a duty to disclose rele-
vant truths to their patients, it is not always clear what
constitutes the ‘truth’. The moral obligation to avoid
harm may outweigh the doctor’s duty to fully disclose
the ‘truth’ where the meaning is unclear, as was the case
for clinicians in our study. Our ﬁndings provide an
understanding of why clinical guidelines are not always
adhered to for virtuous and complex reasons.
Implication for clinicians and policymakers
The updated 2014 NICE clinical guidelines for CKD26
include recommendations to increase proteinuria testing
and not to determine the management of CKD solely by
the age of the patient, which addresses some of the con-
cerns of GPs reﬂected in our study. Anchoring the
meaning and purpose of CKD monitoring by increased
proteinuria testing and assessment of risk, on an individ-
ual patient basis, may help to allay some of the ethical
and moral reservations clinicians expressed around the
medicalisation of ‘normality’ and harm to patients in
being given a disease label.
As national policy moves towards the use of renal
markers that are more closely associated with cardiovascu-
lar risk, such as cystatin C,30 the link between a CKD diag-
nosis and true increased cardiovascular risk will become
more accurate. In turn, this may improve the implemen-
tation of guidance as GPs experience increased congruity
with the strategic and philosophical aims of diagnosis and
monitoring of CKD in primary care.
Unanswered questions and future research
We do not yet know how the new NICE guidance will be
implemented, and how GPs will respond to the introduc-
tion of another eGFR formula (CKD-EPI) which will alter
CKD diagnoses and stages for some patients,26 although
this may lead to some resolution of clinician dissonance
observed in this study. This may present a positive step as it
will limit ‘overdiagnosis’ of CKD and therefore reduce con-
cerns expressed by our participants. However, as the ability
to determine true cardiovascular risk becomes more accur-
ate within the cohort of patients currently identiﬁed as
having CKD, there will be a need for increased under-
standing around how to translate that biomedical knowl-
edge into improved diagnostic and monitoring strategies,
which have clear value to GP and patient.
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